Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”
You may also be interested in...
Genta Postscript: Defunct Company’s Former President Charged With Insider Trading
Loretta Itri told a longtime friend of the negative results of a Phase III study of Genasense in advanced melanoma before the news was public.
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.